WEREWOLF THERAPEUTICS, INC. Amortization of Debt Issuance Costs
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Amortization of Debt Issuance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2025-03-11
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2024-09-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2024-06-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2023 was $60.00K, a 70.44% decline from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2022 was $203.00K.
- WEREWOLF THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2021 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $60.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $60.00K 10-Q · filed 2024-11-07 | $263.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $60.00K 10-Q · filed 2024-08-08 | $263.00K derived: sum of 3 quarters · filed 2024-08-08 | $263.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $60.00K 10-Q · filed 2024-05-03 | $263.00K derived: sum of 2 quarters · filed 2024-05-03 | $263.00K derived: sum of 3 quarters · filed 2024-05-03 | $263.00K derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $203.00K derived: sum of 2 quarters · filed 2024-03-07 | $203.00K derived: sum of 3 quarters · filed 2024-03-07 | $203.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |